[Splenic tuberculosis during psoriasis treatment with infliximab].

Abstract

Psoriasis is a chronic inflammatory disease affecting the skin and occasionally the joints. The biological agents have been engineered to target a specific step in the inflammatory cascade that leads to psoriasis, including tumor necrosis factor, which has a central role in the host defense against Mycobacterium tuberculosis. This is a case report about a psoriatic patient who presented splenic tuberculosis during treatment with infliximab.

• Authors: Gleyce Tavares de Melo Fortaleza, Maria de Fátima de Medeiros Brito, Josemir Belo dos Santos, Ana Roberta Figueiredo, Perla Gomes
• Journal: Anais brasileiros de dermatologia (An Bras Dermatol) 2009 Jul-Aug Vol. 84 Issue 4 Pg. 420-4 ISSN: 1806-4841 [Electronic] Spain
• Vernacular Title: Tuberculose esplênica durante tratamento de psoríase com infliximabe.
• PMID: 19851677 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Dermatologic Agents
• Tumor Necrosis Factor-alpha
• Infliximab

Topics

• Adult
• Antibodies, Monoclonal (adverse effects)
• Dermatologic Agents (adverse effects)
• Humans
• Infliximab
• Male
• Psoriasis (drug therapy)
• Tuberculosis, Splenic (chemically induced)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)